ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

CMV, EBV and BKV Viremia Rate Varied Depending on the Timing of Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression and HLA-Sensitization (HS) Status in Kidney Transplant Patients (KTx Pts)

B. Shin, N. Ammerman, A. Vo, S. C. Jordan, M. Toyoda, S. Sethi

Cedars-Sinai Medical Center, Los Angeles, CA

Meeting: 2020 American Transplant Congress

Abstract number: D-103

Keywords: Co-stimulation, Cytomeglovirus, Epstein-Barr virus (EBV), Immunosuppression

Session Information

Session Name: Poster Session D: Kidney Immunosuppression: Novel Regimens and Drug Minimization

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Viral infections (VI) represent significant morbidity and mortality factors for KTx Pts. We previously showed more VI in BLT-treated Pts compared with CNI Pts and a higher VI risk at early conversion to BLT post-Tx. We also showed less CMV and EBV VI in HS than non-HS Pts due to IVIG and rituximab used for desensitization (DES). Here, we analyzed VI status in HS vs. non-HS KTx Pts who were converted to BLT within (<1yr) vs. (>1yr) post-Tx.

*Methods: 160 EBV sero+ KTx pts (48 HS, 112 non-HS) with conversion to BLT from CNI between 2012 & 2019 (89 Pts <1yr [median 3.6 M, 0.7-12.5 post-Tx), 71 Pts >1yr [median 43.1M, 12.6-117.3]) were included. 128 Pts received lymphocyte depletion and 32 anti-CD25 induction. All received standard viral prophylaxis for 6M post-Tx. CMV, EBV and BKV viremia were monitored by PCR, and viremia with >50 copies/PCR for CMV &EBV and >2500 copies/ml for BKV that required anti-viral therapy were analyzed.

*Results: Overall, EBV viremia was significantly less in HS vs. non-HS, likely due to rituximab depletion of B cell, reservoirs of EBV. There was no difference in CMV and BKV viremia in the two groups. Overall, CMV and BKV viremia was greater in patients converted to BLT <1yr post-Tx. This trend was greater in HS vs. non-HS. In contrast, EBV viremia was significantly greater in Pts converted to BLT >1yr than <1yr post-Tx and this trend was greater in non-HS Pts. There was no significant difference in CMV viremia rate by CMV sero status. 2 PTLD and 2BKAN occurred in 4 non-HS Pts with conversion <1yr.

*Conclusions: Differential viremia rates were observed in KTx Pts who received BLT, depending on the conversion timing and HS status. Recognizing these associations directs higher vigilance in monitoring the higher risk groups.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Shin B, Ammerman N, Vo A, Jordan SC, Toyoda M, Sethi S. CMV, EBV and BKV Viremia Rate Varied Depending on the Timing of Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression and HLA-Sensitization (HS) Status in Kidney Transplant Patients (KTx Pts) [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/cmv-ebv-and-bkv-viremia-rate-varied-depending-on-the-timing-of-conversion-to-belatacept-blt-from-calcineurin-inhibitor-cni-based-immunosuppression-and-hla-sensitization-hs-status-in-kidney-tra/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences